Discover how intellectual property rights protect exclusive pharmaceutical use and brand names in biotechnology, influencing innovation and market dynamics.

The comprehensive report from the bipartisan National Security Commission on Emerging Biotechnology (NSCEB) delivers a “sobering, even frightening,” conclusion: that China is quickly ascending to ...

Jarez Holz says 2026 will be a strong year for biotech stocks. The Mizuho analyst explained why in a recent CNBC interview.

Biotech’s slump may finally be over in 2026. In interviews with BioSpace, Zymeworks’ CEO Ken Galbraith and Zai Lab’s President and COO Josh Smiley explain what’s fueling the comeback.

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum ...

The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not ...